Notice of Change to RFA-DA-22-033, "Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 - Clinical Trial Not Allowed)"
Notice Number:
NOT-DA-21-089

Key Dates

Release Date:

October 19, 2021

Related Announcements

RFA-DA-22-033 - Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 - Clinical Trial Not Allowed)

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this notice is to alert potential applicants to updated language in Funding Opportunity Announcement (FOA) RFA-DA-22-033, "Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 - Clinical Trial Not Allowed)". This change removes limiting language regarding the number of allowable submissions.

The following modification has been made to RFA-DA-22-033:

Currently Reads:

3. Additional Information on Eligibility

Number of Applications

Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

The NIH will not accept duplicate or highly overlapping applications under review at the same time. This means that the NIH will not accept:

  • A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
  • A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
  • An application that has substantial overlap with another application pending appeal of initial peer review (see NOT-OD-11-101)

Applicant organization is allowed to submit only one application.

Modified to Read:

3. Additional Information on Eligibility

Number of Applications

Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

The NIH will not accept duplicate or highly overlapping applications under review at the same time. This means that the NIH will not accept:

  • A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
  • A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
  • An application that has substantial overlap with another application pending appeal of initial peer review (see NOT-OD-11-101)
     

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Sheba K. Dunston, EdD, MPH, CHES
National Institute on Drug Abuse (NIDA)
Telephone: 301-402-1526
Email: Sheba.Dunston@nih.gov


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices